Ventyx Biosciences (VTYX) Stock Forecast, Price Target & Predictions
VTYX Stock Forecast
Ventyx Biosciences stock forecast is as follows: an average price target of $33.86 (represents a 1710.70% upside from VTYX’s last price of $1.87) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
VTYX Price Target
The average price target for Ventyx Biosciences (VTYX) is $33.86 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $60.00 to $6.00. This represents a potential 1710.70% upside from VTYX's last price of $1.87.
VTYX Analyst Ratings
According to 8 Wall Street analysts, Ventyx Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for VTYX stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Ventyx Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 13, 2024 | Emily Bodnar | H.C. Wainwright | $6.00 | $2.98 | 101.34% | 220.86% |
| Jun 06, 2024 | Jeff Jones | Oppenheimer | $10.00 | $5.28 | 89.39% | 434.76% |
| Mar 12, 2024 | Derek Archila | Wells Fargo | $16.00 | $8.42 | 90.02% | 755.61% |
| Mar 12, 2024 | Jeff Jones | Oppenheimer | $12.00 | $8.42 | 42.52% | 541.71% |
| Dec 19, 2022 | - | Goldman Sachs | $50.00 | $32.64 | 53.19% | 2573.80% |
| Nov 17, 2022 | Matthew Harrison | Morgan Stanley | $45.00 | $25.43 | 76.96% | 2306.42% |
| Sep 13, 2022 | Michael Yee | Jefferies | $60.00 | $38.11 | 57.44% | 3108.56% |
| May 12, 2022 | Yasmeen Rahimi | Piper Sandler | $50.00 | $14.53 | 244.12% | 2573.80% |
The latest Ventyx Biosciences stock forecast, released on Jun 13, 2024 by Emily Bodnar from H.C. Wainwright, set a price target of $6.00, which represents a 101.34% increase from the stock price at the time of the forecast ($2.98), and a 220.86% increase from VTYX last price ($1.87).
Ventyx Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $11.00 |
| Last Closing Price | $1.87 | $1.87 | $1.87 |
| Upside/Downside | -100.00% | -100.00% | 488.24% |
In the current month, the average price target of Ventyx Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ventyx Biosciences's last price of $1.87. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 16, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Sep 24, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Jun 13, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Jun 06, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 06, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Mar 12, 2024 | Wells Fargo | - | Overweight | Upgrade |
| Dec 19, 2022 | Goldman Sachs | - | Buy | Initialise |
| Sep 13, 2022 | Needham | Buy | Buy | Hold |
| Sep 12, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 12, 2022 | Credit Suisse | Outperform | Outperform | Hold |
Ventyx Biosciences's last stock rating was published by H.C. Wainwright on Oct 16, 2024. The company gave VTYX a "Neutral" rating, the same as its previous rate.
Ventyx Biosciences Financial Forecast
Ventyx Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $66.71M | $25.00M | - | - | - | - | - | - | - | - | - |
| High Forecast | $66.71M | $25.00M | - | - | - | - | - | - | - | - | - |
| Low Forecast | $66.71M | $25.00M | - | - | - | - | - | - | - | - | - |
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Ventyx Biosciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. VTYX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Ventyx Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict VTYX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Ventyx Biosciences's previous annual EBITDA (undefined) of $NaN.
Ventyx Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $7.77M | $-19.79M | $-38.16M | $-38.87M | $-36.04M | $-36.75M | $-35.33M | $-37.63M | $-38.25M | $-36.57M | $-40.83M |
| High Forecast | $7.77M | $-19.79M | $-38.16M | $-38.87M | $-36.04M | $-36.75M | $-35.33M | $-34.01M | $-32.58M | $-36.57M | $-40.83M |
| Low Forecast | $7.77M | $-19.79M | $-38.16M | $-38.87M | $-36.04M | $-36.75M | $-35.33M | $-41.97M | $-43.21M | $-36.57M | $-40.83M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Ventyx Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VTYX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Ventyx Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Ventyx Biosciences's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to VTYX last annual SG&A of $NaN (undefined).
Ventyx Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $0.11 | $-0.28 | $-0.54 | $-0.55 | $-0.51 | $-0.52 | $-0.50 | $-0.53 | $-0.54 | $-0.52 | $-0.58 |
| High Forecast | $0.11 | $-0.28 | $-0.54 | $-0.55 | $-0.51 | $-0.52 | $-0.50 | $-0.48 | $-0.46 | $-0.52 | $-0.58 |
| Low Forecast | $0.11 | $-0.28 | $-0.54 | $-0.55 | $-0.51 | $-0.52 | $-0.50 | $-0.59 | $-0.61 | $-0.52 | $-0.58 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Ventyx Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VTYX previous annual EPS of $NaN (undefined).
Ventyx Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $1.87 | $33.86 | 1710.70% | Buy |
| GPCR | Structure Therapeutics | $34.17 | $92.40 | 170.41% | Buy |
| REPL | Replimune Group | $10.80 | $24.20 | 124.07% | Buy |
| IMCR | Immunocore | $31.59 | $70.75 | 123.96% | Buy |
| SNDX | Syndax Pharmaceuticals | $15.83 | $34.30 | 116.68% | Buy |
| IDYA | IDEAYA Biosciences | $26.64 | $46.58 | 74.85% | Buy |
| ASND | Ascendis Pharma | $126.51 | $190.21 | 50.35% | Buy |
| PCVX | Vaxcyte | $86.83 | $124.00 | 42.81% | Buy |
| NUVL | Nuvalent | $86.88 | $111.57 | 28.42% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| TVTX | Travere Therapeutics | $17.72 | $21.75 | 22.74% | Buy |
| PTGX | Protagonist Therapeutics | $41.11 | $50.00 | 21.62% | Buy |
| UTHR | United Therapeutics | $363.25 | $358.20 | -1.39% | Buy |
| VRNA | Verona Pharma | $35.66 | $33.86 | -5.05% | Buy |
| ACLX | Arcellx | $87.83 | $83.00 | -5.50% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |